Our in vitro- and in vivo-data thus clearly demonstrate a hypersensitivity phenotype of BRCA2-deficient cells towards TRAIL-R-stimulation, resembling and exceeding the effects of ICL-agents, and could serve as a platform for clinical trials applying TRAIL-R-agonistic antibodies specifically in patients with BRCA2-mutant cancers. This evidence concerns the gene BRCA2 and cancer.